Abstract 21P
Background
The malignant progression of bladder cancer is a key influencing factor for its poor prognosis. In recent years, numerous studies have shown that circular RNA (circRNA) can regulate the expression of genes in multi-levels, which may play a key role in malignant tumors.
Methods
This study applied bioinformatics methods to preliminarily screened the differentially expressed circular RNAs between bladder cancer and corresponding adjacent tissue. Real-time quantitative PCR(RT-qPCR) experiments were performed to identify differentially expressed circular RNAs in cell lines and tissues of bladder cancer. The functional experiments including plate cloning, CCK-8, Edu and xenograft tumor models were implemented to investigate the biological behavior changes of bladder cancer induced by knocking down hsa_circ_0009061 in vitro and in vivo. Bioinformatics methods were applied to predict miRNAs that circular RNA might bind to and the miRNA target genes, and the real-time quantitative PCR, RNA pulldown,dual luciferase reporter experiment and western blot were utilized to explore the mechanism of hsa_circ_0009061 regulating bladder cancer progression.
Results
The bioinformatics analysis and RT-qPCR find that hsa_circ_0009061 was downregulated in cell lines and tissues of bladder cancer. After successfully knocking down hsa_circ_0009061 in bladder tumor cells, functional experiments including plate cloning, Edu and CCK-8 revealed that silencing hsa_circ_0009061 could promote the malignant proliferation of bladder tumor cell lines in vitro. Xenograft tumor modelalso verified that silencing hsa_circ_0009061 could promote tumor formation in vivo. Mechanistic studies have shown that hsa_circ_0009061 can act as a competitive endogenous RNA to bind to hsa-miR-889-3p and regulate the expression of CPEB3, resulting in the malignant progression of bladder cancer.
Conclusions
This study found that hsa_circ_0009061 was downregulated in cell lines and tumor specimens of bladder cancer and could affect the progression of bladder cancer. Mechanistically, hsa_circ_0009061 can bind to hsa-miR-889-3p to regulate the expression of CPEB3, suggesting that hsa_circ_0009061 may be a new treatment option for bladder cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract